Contents

Search

glycoprotein IIb/IIIa inhibitor

Indications: 1) adjunctive agent with angioplasty (PCI)* 2) may be useful for acute coronary syndrome, NSTEMI (not without PCI [2])* * reserved for use at the time of PCI [2] * when used in combination with PCI in CABG graft, may be associated with higher incidence of MI [1] Contraindications: - use in association with thrombolytic therapy - does not improve patient outcomes - increases risk of bleeding [2] Benefit/risk: - adjunctive agent with PCI for patients with STEMI [3] - no mortality benefit - number needed to harm: 116 for major hemorrhage [3] Adverse effects: - hemorrhage

Interactions

drug interactions drug adverse effects (more general classes)

Related

glycoprotein IIB/IIIA

Specific

abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat)

General

antiplatelet agent receptor antagonist

References

  1. Internal Medicine News, July 2005, pg 56
  2. Medical Knowledge Self Assessment Program (MKSAP) 16, 19 American College of Physicians, Philadelphia 2012, 2022
  3. The NNT: Glycoprotein Inhibitors given for Major Heart Attack (STEMI) Patients Receiving Stents or Angioplasty. http://www.thennt.com/nnt/glycoprotein-inhibitors-for-stemi/